San Diego an­ti­fun­gal play­er nabs pri­or­i­ty re­view for blood­stream in­fec­tion treat­ment

Cidara Ther­a­peu­tics wants to make its mark in the world of an­ti­fun­gals, and thanks to the FDA, it may get there soon.

The San Diego-based com­pa­ny an­nounced Tues­day that the FDA has giv­en pri­or­i­ty re­view to its an­ti­fun­gal reza­fun­gin for the treat­ment of can­didemia and in­va­sive can­didi­a­sis — com­mon caus­es of se­ri­ous blood­stream in­fec­tions in hos­pi­tal­ized pa­tients, per the CDC. No new ther­a­pies have been ap­proved in over a decade for the two in­fec­tions, the com­pa­ny said in a press state­ment. Reza­fun­gin’s re­view dead­line date is set for March 22, 2023.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER